No. S 254
Misuse of Drugs Act
(CHAPTER 185)
Misuse of Drugs Act
(Amendment of First and
Fifth Schedules) Order 2015
In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:
Citation and commencement
1.  This Order may be cited as the Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2015 and comes into operation on 1 May 2015.
Amendment of Part I of First Schedule
2.  Part I of the First Schedule to the Misuse of Drugs Act is amended —
(a)by deleting “Bk-MDDMA” in item (1) of paragraph 16 and substituting “bk-MDDMA”;
(b)by inserting, immediately after item (8) of paragraph 16, the following items:
“(8A)
1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4-BMC)
(8B)
1-(4-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 4-Chloromethcathinone or Clephedrone or 4-CMC)”;
(c)by deleting items (10) and (11) of paragraph 16 and substituting the following items:
“(10)
1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one (also known as 3,4-Dimethylmethcathinone or 3,4-DMMC)
(10A)
2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)
(11)
2-(Ethylamino)-1-(4-methylphenyl)propan-1-one (also known as 4-Methylethcathinone or 4-MEC)”;
(d)by deleting items (15) and (16) of paragraph 16 and substituting the following items:
“(14A)
1-(4-Ethylphenyl)-2-(methylamino)propan-1-one (also known as 4-Ethylmethcathinone or 4-EMC)
(15)
1-(4-Fluorophenyl)-2-(methylamino)propan-1-one (also known as 4-Fluoromethcathinone or Flephedrone or 4-FMC)
(15A)
1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro-α-PVP)
(16)
1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one (also known as 4-Methoxymethcathinone or Methedrone or bk-PMMA or PMMC)”;
(e)by deleting item (21) of paragraph 16 and substituting the following item:
“(21)
1-(4-Methylphenyl)-2-(methylamino)propan-1-one (also known as 4-Methylmethcathinone or Mephedrone or 4-MMC)”;
(f)by deleting item (1) of paragraph 18 and substituting the following items:
“(1)
N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group
(1A)
N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135) and its fluoro positional isomers in the pentyl group
(1B)
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (also known as APINACA)”;
(g)by inserting, immediately after item (2) of paragraph 18, the following items:
“(2A)
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as AB-FUBINACA) and its fluoro positional isomers in the phenyl ring
(2B)
4-(2-Aminopropyl)benzofuran (also known as 4-APB)”;
(h)by inserting, immediately after item (4) of paragraph 18, the following items:
“(4A)
7-(2-Aminopropyl)benzofuran (also known as 7-APB)
(4B)
4-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 4-APDB)”;
(i)by inserting, immediately after item (6) of paragraph 18, the following items:
“(6A)
7-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 7-APDB)
(6B)
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25B-NBOMe)”;
(j)by inserting, immediately after item (8) of paragraph 18, the following item:
“(8A)
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25C-NBOMe)”;
(k)by inserting, immediately after item (10) of paragraph 18, the following item:
“(10A)
3,4-Dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (also known as AH-7921) and its dichloro positional isomers in the phenyl ring”;
(l)by inserting, immediately after item (15) of paragraph 18, the following item:
“(15A)
2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H-NBOMe)”;
(m)by deleting items (20), (21) and (22) of paragraph 18 and substituting the following items:
“(20)
[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 or 5-Fluoro-UR-144) and its fluoro positional isomers in the pentyl group
(21)
1-(4-Fluorophenyl)piperazine (also known as 4-Fluorophenylpiperazine or 4-FPP) and its fluoro positional isomers in the phenyl ring
(22)
1-(4-Fluorophenyl)propan-2-amine (also known as 4-Fluoroamphetamine or 4-FA) and its fluoro positional isomers in the phenyl ring”;
(n)by inserting, immediately after item (27) of paragraph 18, the following item:
“(27A)
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25I-NBOMe)”;
(o)by deleting items (29), (30) and (31) of paragraph 18 and substituting the following items:
“(29)
N-Methyl-1-(4-fluorophenyl)propan-2-amine (also known as 4-Fluoromethamphetamine or 4-FMA) and its fluoro positional isomers in the phenyl ring
(30)
N-Methyl-1-(4-methoxyphenyl)propan-2-amine (also known as 4-Methoxymethamphetamine or para-Methoxymethamphetamine or PMMA) and its methoxy positional isomers in the phenyl ring
(31)
N-Methyl-1-(4-methylphenyl)propan-2-amine (also known as 4-Methylmethamphetamine or 4-MMA) and its methyl positional isomers in the phenyl ring”; and
(p)by inserting, immediately after item (38) of paragraph 18, the following items:
“(38A)
Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (also known as BB-22 or QUCHIC)
(38B)
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as 5-Fluoro-PB-22 or 5-Fluoro-QUPIC) and its fluoro positional isomers in the pentyl group
(38C)
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (also known as PB-22 or QUPIC)”.
Amendment of Fifth Schedule
3.  Paragraph 1 of the Fifth Schedule to the Misuse of Drugs Act is amended by deleting items (1) to (13) and substituting the following items:
(1)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA)
(2)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-ADB-PINACA) and its fluoro positional isomers in the pentyl group
(3)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as ADB-PINACA)
(4)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-AB-PINACA) and its chloro positional isomers in the pentyl group
(5)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as AB-CHMINACA)
(6)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-AB-PINACA) and its fluoro positional isomers in the pentyl group
(7)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as AB-PINACA)
(8)N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as PX-2) and its fluoro positional isomers in the pentyl group
(9)N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as PX-1) and its fluoro positional isomers in the pentyl group
(10)1-(1-Benzofuran-5-yl)-N-ethylpropan-2-amine (also known as 5-EAPB) and its 4-yl, 6-yl and 7-yl isomers
(11)2-(2,5-Dimethoxyphenyl)ethanamine (also known as 2C-H) and its dimethoxy positional isomers in the phenyl ring
(12)1-(1H-Indol-3-yl)propan-2-amine (also known as α-Methyltryptamine)
(13)1-(1H-Indol-5-yl)propan-2-amine (also known as 5-IT) and its 4-yl, 6-yl and 7-yl isomers
(14)2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (also known as 2C-I) and its dimethoxy and iodo positional isomers in the phenyl ring
(15)N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-(prop-2-en-1-yl)prop-2-en-1-amine (also known as 5-MeO-DALT)
(16)Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-CHMINACA)
(17)Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as MA-CHMINACA)
(18)Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AMB) and its fluoro positional isomers in the pentyl group”.
Made on 30 April 2015.
LEO YIP
Permanent Secretary,
Ministry of Home Affairs,
Singapore.
[MHA 112/2/0049; AG/LEGIS/SL/185/2015/1 Vol. 1]